Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

Alfonso Quintás-Cardama, Xin Han, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leukemia, even in the absence of thrombocytopenia, suggesting the presence of a hemostatic defect. We tested platelet aggregation in 91 patients with chronic myeloid leukemia in chronic phase either off-therapy (n = 4) or receiving dasatinib (n = 27), bosutinib (n = 32), imatinib (n = 19), or nilotinib (n = 9). All but 3 patients simultaneously receiving imatinib and warfarin had normal coagulation studies. All 4 patients off therapy had normal platelet aggregation. Impaired platelet aggregation on stimulation with arachidonic acid, epinephrine, or both was observed in 70%, 85%, and 59% of patients on dasatinib, respectively. Eighty-five percent of patients on bosutinib, 100% on nilotinib, and 33% on imatinib had normal platelet aggregation. Dasatinib 400 nM induced rapid and marked prolongation of closure time to collagen/epinephrine in normal whole blood on the PFA-100 system. In conclusion, dasatinib and, to some extent, imatinib produce abnormalities in platelet aggregometry testing.

Original languageEnglish (US)
Pages (from-to)261-263
Number of pages3
JournalBlood
Volume114
Issue number2
DOIs
StatePublished - Nov 20 2009
Externally publishedYes

Fingerprint

Platelet Aggregation Inhibitors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Platelets
Protein-Tyrosine Kinases
Platelet Aggregation
Agglomeration
Epinephrine
Leukemia, Myeloid, Chronic Phase
Hemostatics
Warfarin
Coagulation
Arachidonic Acid
Blood
Thrombocytopenia
Collagen
Dasatinib
Blood Platelets
Defects
Imatinib Mesylate
Hemorrhage

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. / Quintás-Cardama, Alfonso; Han, Xin; Kantarjian, Hagop; Cortes, Jorge.

In: Blood, Vol. 114, No. 2, 20.11.2009, p. 261-263.

Research output: Contribution to journalArticle

Quintás-Cardama, Alfonso ; Han, Xin ; Kantarjian, Hagop ; Cortes, Jorge. / Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. In: Blood. 2009 ; Vol. 114, No. 2. pp. 261-263.
@article{646dacfedd3342a3892e261a318e3323,
title = "Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia",
abstract = "Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leukemia, even in the absence of thrombocytopenia, suggesting the presence of a hemostatic defect. We tested platelet aggregation in 91 patients with chronic myeloid leukemia in chronic phase either off-therapy (n = 4) or receiving dasatinib (n = 27), bosutinib (n = 32), imatinib (n = 19), or nilotinib (n = 9). All but 3 patients simultaneously receiving imatinib and warfarin had normal coagulation studies. All 4 patients off therapy had normal platelet aggregation. Impaired platelet aggregation on stimulation with arachidonic acid, epinephrine, or both was observed in 70{\%}, 85{\%}, and 59{\%} of patients on dasatinib, respectively. Eighty-five percent of patients on bosutinib, 100{\%} on nilotinib, and 33{\%} on imatinib had normal platelet aggregation. Dasatinib 400 nM induced rapid and marked prolongation of closure time to collagen/epinephrine in normal whole blood on the PFA-100 system. In conclusion, dasatinib and, to some extent, imatinib produce abnormalities in platelet aggregometry testing.",
author = "Alfonso Quint{\'a}s-Cardama and Xin Han and Hagop Kantarjian and Jorge Cortes",
year = "2009",
month = "11",
day = "20",
doi = "10.1182/blood-2008-09-180604",
language = "English (US)",
volume = "114",
pages = "261--263",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

AU - Quintás-Cardama, Alfonso

AU - Han, Xin

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2009/11/20

Y1 - 2009/11/20

N2 - Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leukemia, even in the absence of thrombocytopenia, suggesting the presence of a hemostatic defect. We tested platelet aggregation in 91 patients with chronic myeloid leukemia in chronic phase either off-therapy (n = 4) or receiving dasatinib (n = 27), bosutinib (n = 32), imatinib (n = 19), or nilotinib (n = 9). All but 3 patients simultaneously receiving imatinib and warfarin had normal coagulation studies. All 4 patients off therapy had normal platelet aggregation. Impaired platelet aggregation on stimulation with arachidonic acid, epinephrine, or both was observed in 70%, 85%, and 59% of patients on dasatinib, respectively. Eighty-five percent of patients on bosutinib, 100% on nilotinib, and 33% on imatinib had normal platelet aggregation. Dasatinib 400 nM induced rapid and marked prolongation of closure time to collagen/epinephrine in normal whole blood on the PFA-100 system. In conclusion, dasatinib and, to some extent, imatinib produce abnormalities in platelet aggregometry testing.

AB - Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leukemia, even in the absence of thrombocytopenia, suggesting the presence of a hemostatic defect. We tested platelet aggregation in 91 patients with chronic myeloid leukemia in chronic phase either off-therapy (n = 4) or receiving dasatinib (n = 27), bosutinib (n = 32), imatinib (n = 19), or nilotinib (n = 9). All but 3 patients simultaneously receiving imatinib and warfarin had normal coagulation studies. All 4 patients off therapy had normal platelet aggregation. Impaired platelet aggregation on stimulation with arachidonic acid, epinephrine, or both was observed in 70%, 85%, and 59% of patients on dasatinib, respectively. Eighty-five percent of patients on bosutinib, 100% on nilotinib, and 33% on imatinib had normal platelet aggregation. Dasatinib 400 nM induced rapid and marked prolongation of closure time to collagen/epinephrine in normal whole blood on the PFA-100 system. In conclusion, dasatinib and, to some extent, imatinib produce abnormalities in platelet aggregometry testing.

UR - http://www.scopus.com/inward/record.url?scp=67651089848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651089848&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-09-180604

DO - 10.1182/blood-2008-09-180604

M3 - Article

C2 - 19414863

AN - SCOPUS:67651089848

VL - 114

SP - 261

EP - 263

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -